Welcome, Guest. Please login or register.
November 25, 2024, 10:45:40 am

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 245
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 209
Total: 209

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Many People Who Start Hepatitis C Treatment Are Lost to Follow-Up  (Read 8167 times)

0 Members and 3 Guests are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Among people who start direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV), a substantial proportion do not maintain all their follow-up appointments.

Publishing their findings in the Journal of Viral Hepatology, Canadian researchers analyzed data from the British Columbia Hepatitis Testers Cohort on 4,777 people who started DAAs.

The study included people with genotype 1 of HCV who were treated with Harvoni (ledipasvir/sofosbuvir), with or without ribavirin, or the Viekira regimen (ombitasvir/paritaprevir/ritonavir; dasabuvir), with or without ribavirin, and people with genotype 3 who were treated with Sovaldi (sofosbuvir) plus ribavirin through the end of 2017.

For more...
https://www.hepmag.com/article/many-people-start-hepatitis-c-treatment-lost-followup

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.